Related Experiment Video

Updated: Jul 24, 2025

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.0K

Optimizing the use of vilobelimab for the treatment of COVID-19

Matthew W McCarthy1

  • 1Department of Medicine, Weill Cornell Medicine, New York, NY, United States of America.

Expert Opinion on Biological Therapy
|July 8, 2023
PubMed

Insights

Vilobelimab, an antibody targeting complement component 5a, received emergency use authorization for severe COVID-19. Treatment in ventilated patients reduced the risk of death by day 60.

Area of Science:

  • Immunology
  • Pharmacology
  • Critical Care Medicine

Background:

  • SARS-CoV-2 infection causes severe COVID-19 through systemic inflammation.
  • Complement component 5a (C5a) is implicated in COVID-19 pathogenesis.
  • Vilobelimab is a monoclonal antibody targeting C5a.

Purpose of the Study:

  • To evaluate the efficacy and safety of vilobelimab in severe COVID-19 patients.
  • To explore the role of C5a inhibition in managing COVID-19-related inflammation.

Main Methods:

  • A randomized, multicenter, adaptive phase II/III clinical trial was conducted.
  • Patients with severe COVID-19 requiring invasive mechanical ventilation were included.
  • Treatment involved vilobelimab plus usual care versus placebo plus usual care.

Main Results:

  • Vilobelimab treatment significantly reduced the risk of death by day 28 and day 60 in mechanically ventilated patients.
  • The study demonstrated a favorable safety profile for vilobelimab.

Conclusions:

  • Vilobelimab is a promising therapeutic option for severe COVID-19.
  • Targeting C5a may mitigate the inflammatory response and improve outcomes in critical COVID-19 patients.
Abstract

Keywords:
C5aCOVID-19ComplementGohibicSARS-CoV-2complementvilobelimab

More Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.4K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.5K

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
250
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
45
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
367
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
202
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573